Access the full Press Release: English Version / French Version
● Aenitis is set to transform the bioproduction industry by addressing the
increasing need for scalable, cost-effective, and highly precise cell processing
technologies.
● Mitis™, the flagship product of its unique Acoustofluidic Technology, is already
used across various applications, from research to clinical and industrial scales,
including cell sorting, isolation, concentration, and washing.
● Funding round led by the European Innovation Council Fund, Quadrivium I fund
(Seventure Partners) and Mifani Invest to support commercial launch and global
expansion.
Paris, France, October 10, 2024-– Aenitis Technologies, a pioneer in acoustic-based cell
manipulation, has successfully closed its equity financing with the European Innovation Council
Fund advised by the European Investment Bank, Quadrivium I fund managed by Seventure
Partners, Mifani Invest, Stamos, Weaving Invest, a few business angels and the company
founders, marking a significant milestone in the deeptech sector. The funding, secured in a two
stage round, will drive the company’s innovative acoustofluidic technology towards commercial
launch and global expansion.
Since its inception, Aenitis has raised a total of €14.5 million in both equity funding and in non
dilutive funding. Supported by public authorities and the European Innovation Council, being one
of the few European players to receive an equity-only support under an EIC Accelerator call, the
company remains committed to advancing bioproduction processes and delivering high-quality
solutions for cell therapy and biomanufacturing.
The funds provided by the investors and the final tranches of non-dilutive funding will be used
to prepare for the commercial launch of Aenitis, demonstrate specific new use cases in
collaboration with key users, and establish distribution channels, initially in Europe, followed by
the US and then selected Asian markets. In addition, the funds will be used to support the final
stages of technology development, improve production lines and refine the already CE-marked
Mitis™ for market readiness.
Among the newcomers to the Company’s Strategic Board, Eric Garnier, former Vice President
and General Manager of Pall Medical, joins the Strategic Board as Independent Chairman and
will be instrumental in accelerating revenue and profit growth and establishing new
partnerships. In addition, Michel Spagnol will represent Mifani Invest and bring his expertise and
network, notably as former Chairman and CEO of Novasep, which will help structure the
Company.
Emmanuel Vincent, CEO of Aenitis, commented: “Our consortium of investors provides not only
significant funding, but also valuable expertise and a network that will help shape the company.
Their involvement is critical to Aenitis’ success, positioning us for a successful market launch
with Mitis™ and future growth while driving innovation in the field of bioproduction”.
Michel Spagnol, new Strategic Board member, representing Mifani Invest, added:
“I am impressed by Aenitis’ technology, which offers significant advantages for
biomanufacturing, including increased yields, reduced processing costs and improved cell
quality. It is highly valuable for cell therapy and other cell-based applications where precision
and gentleness are critical. I look forward to joining Aenitis’ Strategic Board and contributing to
its success.”
Reflecting on the strategic importance of the investment, Svetoslava Georgieva, Chair of the
EIC Fund Board, noted, “This investment is important for the European biomanufacturing sector.
We are happy to support Aenitis’ technology using acoustic waves to manipulate cells with
unmatched precision and gentleness, which is poised to set new standards. The company
represents the innovative and disruptive potential that the EIC actively promotes. This
investment underlines our confidence in their ability to effect meaningful change and drive
innovation on a global scale.”
Setting New Standards for Biotech Manufacturing
Bioproduction is a cornerstone of modern healthcare and biotechnology, enabling the efficient
production of therapeutic cells and biologics. As the industry faces growing demand for scalable
and cost-effective solutions, Aenitis is set to address these challenges with its groundbreaking
technology. A spin-off from CNRS and ESPCI Paris, co-founded by Emmanuel Vincent, Mauricio
Hoyos and Jean-Luc Aider, the company has developed a platform based on acoustic levitation
in flow that enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing
tens of millilitres per minute to be handled. This patented technology uses acoustic waves to
levitate cells without physical contact, minimizing mechanical stress and preserving cell viability
and functionality. This high-precision approach enhances yields, reduces costs, and improves
cell quality, advancing the fields of cell therapy and biomanufacturing.
Aenitis is Leading the Way in Innovating Bioproduction
Aenitis has a robust portfolio of patents covering its technology, including exclusive licenses and
patents in key global markets, underscoring the breadth and strength of our intellectual property
in this field. We are currently completing development, optimizing production lines and refining
our offerings to meet the highest standards.
Our technology offers significant advantages for biomanufacturing, including increased recovery
yields, reduced processing costs and improved cell quality. It is particularly valuable in cell
therapy and other cell-based applications where precision and gentleness are critical. By
addressing the key challenges of scaling up production and ensuring high quality results, Aenitis
is poised to become a leading player in the bioproduction and cell therapy markets.
